AMLX Amylyx Pharmaceuticals, Inc.

26.20USD-1.58%Mkt Cap: 3.37B USDP/E: —

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provid…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap3.37B USD
Enterprise Value2.66B USD
Revenue (TTM)—
Gross Profit0 USD
Net Income (TTM)-144.74M USD
Revenue/Share—
Last Price26.20 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees136
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-22.22
PEG—
EV/EBITDA-15.16
EV/Revenue—
P/S—
P/B4.47
EPS (TTM)-1.43 USD
EPS (Forward)-1.18 USD
52W Range
10.8351% of range41.13
52W High41.13 USD
52W Low10.83 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-47.41%
ROA-43.51%
ROIC—
ROCE-49.46%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-123.34M USD
CapEx (TTM)138.00K USD
FCF Margin—
FCF Yield-2.39%
Net Debt-763.19M USD
Net Debt/EBITDA4.35
Net Debt/FCF—
Balance Sheet
Debt/Equity0.02
Current Ratio26.81
Quick Ratio26.54
Book Value/Sh5.86 USD
Cash/Share5.97 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)43.00 USD
Upside (mean)+64.1%
Target Range25.00 USD – 57.00 USD
25.00+64.1% to mean57.00
# Analysts11
Ownership
Shares Out.128.56M
Float112.83M
Insiders6.77%
Institutions104.88%
Short Interest
Short Ratio9.9d
Short % Float12.41%
Short % Out.9.97%
Shares Short12.82M
Short (prev mo.)12.67M
Technical
SMA 5029.52 (-11.2%)
SMA 20020.86 (+25.6%)
Beta-0.08
S&P 52W Chg12.08%
Avg Vol (30d)1.35M
Avg Vol (10d)1.63M
Technical Indicators
RSI (14)39.8
MACD-0.2428
MACD Signal0.1077
MACD Hist.-0.3505
BB Upper31.62 USD
BB Middle28.66 USD
BB Lower25.69 USD
BB Width20.70%
ATR (14)1.727 USD
Vol Ratio (20d)1.29x

About Amylyx Pharmaceuticals (NASDAQ: AMLX)

›

Amylyx Pharmaceuticals (NASDAQ: AMLX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 136 employees.

The shares were at 26.20 USD on 19 November 2026, up 97.9% over 52 weeks. Its 52-week range is 10.83 USD to 41.13 USD: the price is 36.3% below the high and 141.9% above the low.

Its market capitalisation is 3.37B USD.

Amylyx Pharmaceuticals reports return on equity of -47.4% and an operating margin of 0.0%.

It holds more cash than debt, a net cash position of 763.19M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 11 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 43.00 USD is 64.1% above the current price. The next earnings report is expected on 4 March 2027.